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Abstract  
Advances in the generation and interpretation of proteomics data have spurred a 
transition from focussing on protein identification to functional analysis. Here, we 
review recent proteomics results that have elucidated new aspects of the role and 
regulation of signal transduction pathways in cancer using the epidermal growth 
factor receptor (EGFR), ERK and breakpoint cluster region (BCR)–ABL1 networks as 
examples. The emerging theme to understand cancer signalling as networks of 
multi-protein machines that process information in a highly dynamic environment 
that is shaped by changing protein interactions and posttranslational modifications 
(PTMs). Cancerous genetic mutations derange these protein networks in complex 
ways that are tractable by proteomics. 
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While the causes of cancer lie in mutations or epigenetic changes at the genetic level, their 
molecular manifestation is the dysfunction of biochemical pathways at the protein level. 
Therefore, it is only by studying the proteome that we can extract functional understanding of the 
pathways that are deranged in cancer. Rather than just identifying proteins, functional proteomics 
focuses on the generation of information about proteins, such as expression levels, PTMs and 
activity, which directly contribute to a functional understanding of the biological system. 
Functional proteomics feeds directly into the systematic analysis of biochemical networks, often 
using mathematical modelling or other systems biology tools. It also provides readouts for 
chemical biology and chemical genetics necessary to interpret the action of drugs.  
The growing interest in functional proteomics is not only fuelled by the prospect of a true 
functional understanding, but also by significant improvements in technology and methodology. 
Advances in mass spectrometry (MS) have extended the sensitivity, accuracy and speed of analysis 
to now routinely enable the identification of several thousand proteins per experiment.  The 
introduction of MS methods for accurate relative and absolute protein quantification, and the 
large scale analysis of PTMs, such as phosphorylation and ubiquitinylation, has enabled truly 
functional proteomics. MS is now joined by antibody and protein-protein interaction arrays1, 
fluorescence and flow cytometry based detection of proteins and PTMs2, and optical spectroscopic 
methods of proteome analysis3, 4. These latter techniques are promoted by an ever increasing 
repertoire of specific antibodies against proteins and PTMs, and bring single cell proteomics into 
reach.  
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Proteomics has been widely applied to cancer research and the mapping of cancerous 
signalling pathways, and the vast literature exceeds the scope of a single review. Therefore, we will 
use three main cancer pathways, EGFR, BCR-ABL1 and ERK as examples to elaborate some of the 
new paradigms in cancer signalling that owe their discovery to proteomics. The EGFR network is 
frequently altered in various human cancers, and has been extensively studied using proteomics 
both at the level of the receptor and the downstream pathways. BCR-ABL1 stands out amongst 
oncogenes as chronic myelogenous leukaemia (CML), which is caused by this fusion gene, is with 
few exceptions strictly dependent on BCR-ABL1 function5. Thus, BCR-ABL1 signalling could reveal 
the minimum assortment of pathways required for transforming a human cell. The ERK pathway is 
a critical effector of both the EGFR and BCR-ABL1 pathways. Hence, although other important 
pathways - such as the AKT or mTOR pathways - are not discussed here, our selection allows us to 
elaborate general principles and representative new insights into cancer signalling pathways that we 
have gained through proteomics. As technological and methodological advances are integral to 
functional proteomics, we briefly discuss the experimental approaches, although the emphasis is on 
the biological findings.  
We begin with discussing protein-protein interactions. Most cellular processes, including 
signal transduction, require the coordinated formation of multiprotein complexes. A main focus in 
functional proteomics has been to analyse the formation of specific protein-protein interactions and 
the consequent assembly of macromolecular protein complexes, in particular how these assemblies 
are regulated by scaffolding proteins and PTMs, and how they affect pathway function. We then 
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discuss selected PTMs that are associated with cancer pathways. While phosphorylation and 
glycosylation have dominated the post-translational area, we increasingly realise that a large range 
of modifications, including ubiquitinylation, play critical roles in cellular regulation. We conclude 
with an outlook towards single cell proteomics and clinical relevance of functional cancer 
proteomics. 
 
Protein-protein interactions 
Protein-protein interactions play important roles in cellular processes. However, deconvoluting the 
complex nature of these interactions has proved to be a difficult undertaking.  Stable protein 
assemblies function as ‘molecular machines’ in all cellular processes from transcription machineries 
in the nucleus, to ribosomes that translate mRNA into proteins and molecular motors that generate 
the force for intracellular transport and cell motility. These stable protein complexes are highly 
amenable to proteomic analysis, and powerful isolation procedures have been developed to purify 
stable protein complexes for MS analysis. They usually employ tandem affinity purification (TAP)-
tags, which allow the efficient purification of stable protein complexes by a sequential pulldown-
elution-pulldown protocol6. Genome wide interaction studies7, 8 using this methodology showed 
that the yeast proteome is organized into 500-550 protein complexes, thus experimentally 
confirming the concept that organization based on protein-protein interactions can specify 
biological functions. Does this concept also apply to molecular information processors in 
mammalian cells? 
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In principle, dynamically changing protein interactions could provide the speed, plasticity 
and compartmentalization needed to process signals that encode both temporal and spatial 
information. However, these associations may be fleetingly transient, featuring complex dynamics 
and stoichiometries between different complexes competing for the same component. Thus, these 
interactions are often regulated through transient PTMs, such as phosphorylation. Specific 
phosphorylation-dependent binding motifs have been identified on many signalling proteins. For 
example, activated receptor tyrosine kinases (RTKs) phosphorylate tyrosines in their cytoplasmic 
kinase domains that provide binding sites for downstream effectors that direct the assembly of 
transient signalling complexes 9-11. RTKs, especially those of the ErbB family, are often 
overexpressed or mutated in cancer, resulting in the assembly of functionally aberrant signalling 
complexes9, 12.  
The technical aspects of mapping protein interactions in signalling pathways were covered 
in recent reviews13-15.  The methodologies rely on the application of quantitative mass spectrometric 
techniques16 (Box 1) and often require the generation of dynamic interaction maps17, 18.  One of the 
main advantages is that the quantitative techniques can separate true interactors from 
contaminations19. However, significant challenges remain.  Methodologies for measuring the 
specific occupancy of PTM sites on individual protein molecules are limited. Similarly, we cannot 
resolve the specific functions of individual proteins within different complexes, which is akin to 
having a corporate organization chart with all the names but no affiliations to departments. 
However, emerging evidence suggests that signal transduction uses a matrix management approach, 
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where one component fulfils different tasks in different complexes (or departments). Mapping this 
matrix is further complicated by the fact that the structure can change dynamically over time, and 
certain complexes may only be necessary for a limited time in order to activate their downstream 
biological pathways.  
This provides a major challenge, as it may be failures in the matrix management that drive 
cancer rather than individual mutations altering one function. The crosstalk between protein 
complexes also contributes to the robustness of cancer signalling by providing modularization20 and 
generating molecular heterogeneity21 that together allow rapid and versatile adaptation. This view is 
encapsulated in the concept of non-oncogene addiction, which highlights the importance of normal 
pathways supporting the biological effects of mutated pathways22. This concept has wide 
ramifications for the design of rational cancer therapies and the identification of promising targets. 
The hope is that the common phenomenon of cancer drug resistance can be conquered by the 
parallel targeting of oncogenic pathways and non-oncogene addictive alterations.  
 
Protein complexes. The EGFR pathway is one of the most extensively studied signalling pathways 
that is relevant to cancer23 and the EGFR interactome is one of the most well described both 
biochemically24 and theoretically 25, 26 (Fig. 1).  A major question is how EGFR coordinates diverse 
biological responses and how response specificity is generated. Functional proteomics has 
deciphered the components of protein complexes formed by EGFR and has also contributed to an 
understanding of the topological organisation the downstream signalling pathways. 
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Using MS-based quantitative proteomics to analyse proteins interacting with 
phosphopeptides that are phosphorylated in response to ligand binding showed that the four 
members of the ErbB family (EGFR is also known as ERBB1) have differential preferences for 
interaction partners27. Interestingly, growth factor receptor-bound protein 2 (GRB2), which initiates 
activation of the ERK pathway, and PI3K, which activates the AKT pathway, have several binding 
sites on one receptor. Multimeric binding could be a simple mechanism to transmit strength of the 
input into these pathways. A complementary approach used protein microarrays comprising most 
known SH2  and phosphotyrosine binding (PTB) domains in the human genome to measure the 
dissociation constants of each domain for 61 peptides that are physiologically tyrosine 
phosphorylated when ERBB1-4 are activated28. The resulting systematic interaction maps showed 
that the binding complement differs between receptor dimers, with ERBB2-ERBB3 having the most 
interactions followed by EGFR-ERBB3>EGFR-ERBB2>EGFR-EGFR. This distribution correlates 
with the transforming potencies of ErbB dimers29, 30 indicating that an increase in interaction 
partners enhances oncogenicity. Interestingly, EGFR and ERBB2 (also known as HER2), but not 
ERBB3, became increasingly promiscuous with increasing expression levels or activation state 
resulting in the binding of more proteins and the activation of more signalling pathways at higher 
concentrations28, which may explain why they are often overexpressed in cancer.  Comparing the 
interactors identified in these studies shows overlaps but also differences, for example signal 
transducer and activator of transcription 5 (STAT5) was only found to bind to EGFR and ERBB4 in 
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the MS study. These differences could be due to different experimental systems or reflect differences 
in the technologies used. 
These studies also suggested that the biological specificity of receptor signalling is 
determined by the composition of the signalling complexes they assemble; and the ligand induced 
changes in their interactomes. Implicit in this hypothesis is the assumption that changes in the 
receptor interactome are propagated throughout the network to affect downstream protein 
interactions and thereby dynamically shape the network topology used to transduce a signal. This 
theory was recently confirmed by the analysis of the dynamic ERK interactome in the control of 
differentiation versus proliferation in PC12 cells31. The ERK pathway consists of a three-tiered 
kinase cascade, Raf – MEK –ERK, and is a main effector of EGFR signalling (Fig. 1) that mediates 
many responses to EGF that are subverted in cancer, such as cell proliferation, transformation, 
differentiation, migration and survival. Stable isotope labelling with amino acids in culture 
(SILAC)-based quantitative proteomics was used to determine changes in the ERK interactome in 
response to nerve growth factor (NGF; which induces differentiation) and EGF (which induces 
proliferation).  The results increased the number of proteins identified in the ERK interactome from 
170 proteins32 to >280. Importantly, 60 protein interactions changed in a differentiation-dependent 
manner. Detailed analysis of a subset of ERK interactors showed that they regulate the pathway at 
different steps, including the activation kinetics of ERK, crosstalk with other pathways and 
phosphorylation of transcription factors. These biochemical data were incorporated into a 
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mathematical model revealing that the EGF and NGF pathways are under a distributed control 
mechanism rather than governed by a single master switch.  
These results show that signalling pathways critically rely on protein interactions, which 
distribute control throughout the network, and that quantitative interaction proteomics is a 
formidable tool to map these pathways and their topologies. Furthermore, these findings predict 
that it is difficult to disrupt signalling networks by interventions targeting a single node, adding a 
mechanistic explanation to the clinical experience that the efficacy of single agent cancer therapies is 
usually limited. These studies are complemented by the analysis of downstream phosphorylation 
events that we discuss further below.  
The proteomic studies of the EGFR pathway demonstrate how signalling specificity is 
achieved through regulated protein interactions, and how receptor overexpression can expand the 
scope of interaction partners sufficiently to drive oncogenesis.  This theme of oncogenesis resulting 
from the unwanted spread of signalling into many pathways due to an expansion of the number of 
protein complexes assembled is more clearly demonstrated when this regulation is usurped by an 
oncoprotein. BCR-ABL1 is an oncogenic fusion protein that results from the chromosomal 
translocation that causes chronic myelogenous leukaemia (CML), and inhibition of its kinase 
activity can profoundly reverse the disease33, 34. The translocation that results in BCR-ABL1 is a rare 
case where human tumorigenesis can be tied to a single genetic event both based on molecular 
evidence and the unprecedented clinical success of the BCR-ABL1 inhibitor imatinib5.  
 10
What causes this exception? Classical biochemical studies suggested that BCR-ABL1 is a 
constitutively active tyrosine kinase and ‘super-adaptor’ that interacted with almost every pathway 
implicated in oncogenic transformation of haematopoietic cells and fibroblasts35 (Fig. 2). The 
challenge was to define which of these pathways is required for BCR-ABL1-induced transformation. 
An interaction proteome screen of BCR-ABL1-associated proteins revealed a network of several 
hundred proteins as direct or indirect interactors36. Evaluation of the highly connected hubs only 
revealed seven core components: GRB2, Src homology 2 domain containing transforming protein 1 
(SHC1), CRK, CBL, p85 (also known as PIK3R2), suppressor of T-cell receptor signaling 1 (STS1, also 
known as UBASH3B) and SH2 domain-containing inositol phosphatase 2 (SHIP2, also known as 
INPPL1), which coordinate a signalling network comprising several hundred proteins (Fig. 2). 
Interestingly, many of the core components are scaffolds suggesting that BCR-ABL1 signalling is 
orchestrated through propagating layers of protein complexes. BCR-ABL1 kinase inhibitors 
disrupted this network leading the authors to conclude that the action of theses drugs should be 
considered as interfering with the equilibrium state of an intricate network of protein complexes 
rather than just inhibiting a single component.  Given that several proteins interact with more than 
one of the seven core components, even the perturbation of a single interaction should have 
repercussions throughout the network as it could shift the equilibrium composition of other 
complexes. This view may become important in the quest for alternative strategies that can 
circumvent resistance to tyrosine kinase inhibitors.  
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The big question is, of course, whether these findings from cultured cells translate into the 
clinic. This question was addressed mainly by using reverse phase protein microarrays, where 
lysates of tumour samples are arrayed and interrogated with antibodies. This strategy only permits 
targeted studies, but can examine large numbers of patients and functions with the limited amounts 
of tissue, such as tumour biopsies, that is typically available in clinical settings. Such studies have 
yielded clinically useful information and are discussed in detail by Brennan et al. in this issue37.   
 
Protein Scaffolds. Having made the point that protein interactions are important, the question is 
what holds them together? Through binding two or more client proteins simultaneously scaffold 
proteins generate platforms that alter signalling kinetics, control crosstalk between signalling 
pathways and insulate elements from each other. Although the role of scaffolds in cancer still needs 
to be elaborated, we will briefly discuss them as they play fundamental roles in regulating both 
steady state and acute response kinetics of many pathways involved in cancer. They seem to be most 
relevant to mechanisms of non-oncogene addiction22, whereby normal components of signalling 
networks support the aberrant components. Aberrations in ERK signalling are common in cancer38 
and hence we discuss two ERK pathway scaffolds. 
The kinase suppressor of Ras (KSR) proteins scaffold the three-tiered Raf-MEK-ERK kinase 
module and contribute to the regulation of its signalling dynamics and spatio-temporal control. 
KSR1 is not essential for, but enhances ERK activation39. Importantly, knocking out KSR1 restrains 
transformation by oncogenic HRAS-G12V in cultured cells40 and HRAS-G12V driven skin 
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carcinogenesis in mice41. KSR1 constitutively interacts with MEK and the complex translocates to 
the plasma membrane on mitogen stimulation42. MEK bound to KSR1 also promotes the 
recruitment of BRAF, which enhances MEK phosphorylation by BRAF. Interestingly, ERK binding 
induces feedback phosphorylation of KSR1 and BRAF by ERK, which promotes the dissociation of 
BRAF and KSR1 and release from the plasma membrane into the cytosol. It is unclear whether this 
is a purely negative feedback pathway that limits ERK activation, or whether this feedback also has a 
role in ensuring the turnover of clients on the scaffold and in localising the signal. In addition, KSR1 
directly activates Raf kinases allosterically by forming side-to-side dimers43. KSR1 selectively 
interacts with ERK dimers and confines ERK signalling to cytosolic substrates and the expression of 
ERK point mutants that prevent its dimerization counteracts cellular transformation in vitro and 
tumour development in mouse xenograft models44. Thus, KSR1 can control several aspects of ERK 
signalling including substrate specificity and spatio-temporal activation kinetics. 
Recently, the KSR2 interactome was studied using quantitative MS-based proteomics to 
compare KSR2 binders with and without tumour necrosis factor-TNF) stimulation45. Of >100 
proteins potentially in the complex approximately 40 were recruited on TNF stimulation, 
highlighting the highly dynamic properties of this signalling complex. Interestingly, KSR2 recruited 
ARAF rather than RAF1 or BRAF. ARAF is a poor activator of MEK, and its main, kinase-
independent, function is as an inhibitor of the pro-apoptotic mammalian STE20-like protein kinase 
2 (MST2, also known as STK3) pathway46 indicating that KSR2 may have a role in redirecting ARAF 
to the ERK pathway. As scaffolding vastly accelerates reaction rates by co-localising enzyme and 
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substrate47, KSR2 bound ARAF is expected to be an effective MEK activator. Thus, this shift of 
ARAF from its anti-apoptotic function in the MST2 pathway to the mitogenic ERK pathway may 
contribute to oncogenic transformation.  
A detailed comparison of the KSR1 and KSR2 interactomes showed the similarity of these 
scaffolds in promoting RTK-mediated ERK signalling, but also identified specific interactions. For 
example, the calcium dependent phosphatase calcineurin only binds to KSR248. In response to 
calcium signals calcineurin dephosphorylates the 14-3-3 binding sites on KSR2, which permits 
KSR2 membrane recruitment and activation of the ERK pathway48.  Another proteomic study 
showed that KSR2 binds to AMP kinase (AMPK, also known as PRKAB1) mediating its stimulatory 
effects on glucose uptake and fatty acid oxidation49. This observation raises an interesting 
hypothesis: that KSR2 may coordinate links between mitogenic signalling and metabolic pathways 
by binding and coordinating the functions of ARAF and AMPK. ARAF can bind and inhibit 
pyruvate kinase M2 (PKM2)50. In many cancers PKM2 is aberrantly expressed in its low activity 
dimeric form, which favours aerobic glycolysis that is the hallmark of the Warburg effect51.  Thus, 
KSR2 could enhance both AMPK mediated glucose uptake and PKM2 inhibition by ARAF, thereby 
promoting the Warburg effect and tumour growth. Consequently, KSR2 downregulation should 
ameliorate the Warburg effect and slow tumour growth, a prediction that is easily testable as Ksr2-/- 
mice are available49.	
The above examples illustrate the key role of protein complexes in signalling, but equally 
highlight the importance of dynamic changes in the interactions that ensure the proper 
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interpretation of the signal and the response to it. Conceptually, this view has significant 
implications. They include the notion that connections in signalling pathways are not hardwired, 
that a protein with a defined biochemical function can adopt different biological functionalities as 
part of different protein complexes, and that the kinetics of signalling specificity intimately involves 
dynamic changes in protein interactions. How are they brought about? Undoubtedly, PTMs are a 
salient part of the answer. The specific roles of PTMs in determining protein complex formation are 
just emerging, but many proteomic techniques for PTM analysis are available. In the following 
section we will briefly review how these technologies were applied to study of dynamic processes in 
cell signalling. 
 
PTMs  
PTMs are widely studied dynamic processes in cell signalling, which is not surprising considering 
the fundamental roles they play in regulating signalling pathways, and many studies have mapped 
cancer-associated PTMs.  Phosphorylation of serine, threonine and tyrosine residues have received 
the most attention from the proteomics community, although ubiquitinylation, acylation and 
glycosylation are coming into the limelight. O-linked N-acetylglucosamine acylation (O-
GlcNAcylation) is also receiving significant interest mainly due to its competing role in regulating 
phosphorylation by blocking potential phosphorylation sites.   
 
Phosphorylation. Quantitative methods for the study of protein phosphorylation have been 
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described elsewhere13, 52-56. The first phosphoproteome to be extensively studied was that of EGFR 
activation (reviewed by Blagoev24), but several other RTK  pathways have now been described.    
Global tyrosine phosphorylation is usually mapped using enrichment with anti-
phosphotyrosine antibodies and subsequent MS analysis. Employing this method, both time course 
studies of EGF induced tyrosine phosphorylation and comparisons of signalling between different 
RTKs were performed57. For instance, SILAC based quantitative proteomics was used to compare 
tyrosine phosphorylation induced by EGF versus platelet derived growth factor (PDGF) in human 
mesenchymal stem cells58. EGF induces osteogenic differentiation while PDGF sustains 
proliferation and migration59. Most tyrosine phosphorylation events were common to either growth 
factor, except that the PI3K pathway was exclusively stimulated by PDGF. Inhibiting PI3K 
converted PDGF into a differentiation factor, elegantly demonstrating that biological specificity of 
RTK signalling is encoded by distinct biochemical differences in downstream signalling pathways 
arising from the protein complexes assembled at RTKs. A more recent study analysing tyrosine 
phosphorylation induced by EGF in human mammary epithelial cells revealed significantly 
different stoichiometries of phosphorylation at different sites within the same protein60 suggesting 
an intricate temporal and dynamic regulation.  
This strategy was also successfully used to map the tyrosine phosphorylation network 
induced by cancer-associated EGFR mutants. Glioblastoma  or astrocytoma grade IV, a highly 
malignant brain tumour, often expresses a truncated EGFR mutant, EGFRvIII, which is expressed 
from an amplified gene locus and enhances malignant behaviour in a dose dependent manner61. 
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SILAC analysis of glioblastoma cell lines expressing different EGFRvIII levels and a kinase dead 
EGFRvIII as a control revealed that increasing EGFRvIII expression shifts signalling from ERK and 
STAT3 towards the PI3K pathway and also induce phosphorylation and transactivation of the 
hepatocyte growth factor receptor MET62. Consequently, combining EGF and MET inhibitors 
synergized to kill glioblastoma cells in vitro, producing a rational drug combination based on 
phosphoproteomics data.  
Another proteomics study in non-small-cell lung cancer (NSCLC) cell lines compared 
phosphotyrosine signalling induced by wild-type EGFR, mutation-activated EGFR and 
overexpressed MET63. It revealed networks that extensively overlapped in the regulation of cell 
adhesion, motility, proliferation and survival. Interestingly, mutant EGFRs preferentially induced 
phosphorylation of cytoskeletal proteins, scaffolds implicated in cytoskeletal regulation and 
motility, as well as negative feedback inhibitors of EGFR signalling, such as sprouty 1 (SPRY1), 
SPRY2, SPRY4, and mitogen-inducible gene 6 (MIG6, also known as ERRFI1). The functional 
effects are largely unknown, but it is tempting to speculate that mutant EGFRs can sabotage the 
function of physiological feedback inhibitors. This hypothesis is consistent with observations that 
EGFR feedback inhibitors are often downregulated in cancers64. Crosstalk between MET and 
mutant EGFRs provided mutual activation of the respective receptors and downstream signalling 
pathways63. Interestingly, the sensitivity to EGFR and MET inhibitors as measured by biochemical 
outputs correlated with the extent of control of the respective receptors over the downstream 
network. This puts an interesting twist on the observation discussed above that EGFR oncogenicity 
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increases with the number of pathways it engages 28-30 as such functional expansion should also 
increase the vulnerability of the downstream network to receptor inhibition. The available clinical 
experience with EGFR inhibitors shows that spectacular regressions are achievable in patients with 
NSCLC, but this only occurs in a small subset of patients and without lasting effect65.  
Does this reflect an arms race between increasing fragility and adaptive potential of RTK 
networks simultaneously afforded by the recruitment of an increasing number of downstream 
effectors?  This hypothesis suggests the counterintuitive approach to combine EGFR inhibitors with 
inhibitors of downstream pathways in order to boost drug efficacy and prevent resistance. The 
combined inhibition of a receptor and a downstream effector could offer simple, general and hence 
attractive guidelines for the design of combination therapies and seems worthwhile exploring 
further.  
A large scale phosphotyrosine proteomic screen using 41 NSCLC cell lines and >150 NSCLC 
tumours found a large number of RTKs, including EGFR and MET, and non-RTKs were activated66.  
The significance of most of these kinases for the pathogenesis of NSCLC is unknown, but an 
important prediction of this study is that the drug responsiveness of individual tumours should be 
highly dependent on whether these activated kinases function as part of hierarchical networks or in 
independent pathways. If they form hierarchical networks, inhibition of the master kinase will be 
therapeutically effective, as demonstrated by the spectacular efficacies of BCR-ABL1 inhibitors in 
CML. If theses kinases function in independent networks or as part of redundant topologies, a 
combination therapy seems necessary.  Therefore, for personalized therapy it will be important to 
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map kinase activation profiles onto network connectivity maps that control specific biological 
responses. This idea is also now adopted by the pharmaceutical industry, especially for kinase 
inhibitor screening (Box 2). 
The idea to correlate phosphotryosine networks with specific biological behaviour was also 
borne out in studies on the effects of human ERBB2 in human mammary epithelial cells (HMECs)67, 
68. ERBB2 is overexpressed in ~25% of breast cancers and strongly correlates with poor prognosis. 
Although ERBB2 lacks a known ligand, it can heterodimerise with EGFR and alter EGFR signalling. 
Quantitative MS based on isobaric tag for relative and absolute quantitation (iTRAQ) labelling  was 
used to map phosphotyrosine networks in parental HMECs and HMECs engineered to overexpress 
ERBB2 stimulated with either EGF or heregulin (also known as neuregulin 1, NRG1)67. The results 
show that in ERBB2 overexpressing cells EGF stimulates migration through multiple signalling 
pathways, while heregulin uses a subset of the migration network. Applying regression-based 
computational modelling identified combinations of phosphorylation sites that correlate with 
proliferation and migration. Subsequent refinement of the model68 permitted the identification of 
phosphotyrosine network elements that differentially control migration and proliferation. This 
culminated in the elaboration of nine phosphorylation sites on six proteins, associated with the 
PI3K pathway and endocytosis, which served as a ‘network gauge’ that captured the predictive 
capability of the full model. This result also elegantly demonstrates the analytical power added by 
computational modelling to the interpretation of complex dynamic datasets.  
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Phosphoserine and phosphothreonine antibodies are less well developed than 
phosphotyrosine antibodies, and most global phosphoproteome studies employ chromatographic 
enrichment technologies. They usually exploit the propensity of TiO2 or Fe3+ to interact with 
phosphate groups, and are often combined with a preceding separation step that counterselects 
phosphopeptides such as strong cation exchange columns69.  This approach is available in several 
variations, which enrich overlapping but distinct fractions of the phosphoproteome70. It is now 
possible to identify 10-20,000 phosphorylation sites. For instance, proteomic analysis of 
phosphorylation induced by the fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication 
(ITD) mutant tyrosine kinase quantified >12,000 phosphorylation sites and demonstrated 
subcellular localisation-specific signalling71. FLT3-ITD consists of in-frame tandem duplications of 
the juxtamembrane domain and is the most frequent oncogenic FLT3 mutation in acute myeloid 
leukaemia (AML), causing constitutive activation of FLT3 and retardation of trafficking through the 
endoplasmic reticulum (ER). When localized at the ER, FLT3-ITD aberrantly activates STAT5 
signalling, but fails to activate the PI3K and ERK pathways that are targets of ligand activated wild-
type FLT3. By contrast, when located at the membrane FLT3-ITD preferentially activates PI3K and 
ERK over STAT5. These pathway specific effects were reflected in the global phosphoproteome and 
also helped identify putative downstream targets of AKT and proviral integration site (PIM) 
kinases.  
An interesting approach to functional studies is to combine global phosphoproteomics with 
small interfering RNA (siRNA) knockdown studies. An example is the quantitative proteomic 
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assessment of early signalling events in integrin signalling 72. Integrin mediated cell adhesion and 
anti-apoptotic signalling is essential for cancer cell spread and invasion. SILAC combined with 
immobilized metal ion affinity chromatography (IMAC) enrichment showed that >500 
phosphorylation sites in 357 proteins changed when integrins interacted with collagen, a common 
integrin ligand in the extracellular matrix.  siRNA screens against 33 of these proteins with kinase or 
phosphatase activity identified three integrin regulated kinases, p21-activated kinase 2 (PAK2), G 
protein-coupled receptor kinase 6 (GRK6) and DBF4, which are critically involved in cell migration. 
Recent evidence suggests that these proteins are deregulated in cancer. PAK2 is hyper-
phosphorylated in ovarian cancer73, while an siRNA screen identified GRK6 as required for the 
viability of myeloma cells but not normal cells74. DBF4 is a regulatory subunit of the cell cycle kinase 
CDC7 and this complex is overexpressed in a variety of cancer cell lines and cancers75. 
The focus on phosphoproteomics in recent years, and the application of functional 
proteomics methods76, led to the identification of O-GlcNAcylation as an important PTM in 
signalling. As O-GlcNAcylation occurs at serine and threonine residues that are also targets for 
phosphorylation, they mutually exclude each other resulting in a dynamic crosstalk between 
phosphorylation and O-GlcNAcylation77. Although many of the (patho)physiological consequences 
of this crosstalk remain to be explored it has been implicated in a number of diseases including 
cancer78 and demonstrated to be critical for cellular processes that are important in cancer biology, 
such as cytokinesis79.  The application of improved MS techniques (such as electron-transfer 
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dissociation) for detecting O-GlcNAcylation80 or the parallel detection of phosphorylation and 
glycosylation81 will likely increase attention to this field. 
 
Ubiquitinylation. Ubiquitinylation and the proteosomal pathway play key roles in oncogenesis 
andcancer82-88 (Fig. 3), typified by the tumour suppressor p5389, 90, and are being investigated as 
pharmaceutical targets91-94.  Since the early use of functional proteomics to identify the structure and 
substrate specificity for the S-phase kinase-associated protein 1 (SKP1)–cullin 1 (CUL1)–F-box 
(SCF) complex95, 96, this method has continued to play a significant role in the study of 
ubiquitinylation, in identifying both the components of the ligase complexes and the 
ubiquitinylation of proteins97. Recent studies have also focused on the non-classical ligases, such as 
the damage-specific DNA binding protein 1 (DDB1)-CUL4A -regulator of cullins 1 (ROC1, also 
known as RBX1) E3 ubiquitin ligase, a complex that lacks the SKP1-like adaptor and is involved in 
the regulation of DNA repair98.  TAP affinity purification of the complex and subsequent MS 
analysis were used to identify a novel family of 16 WD domain  containing proteins that recruit the 
substrate to the complex99. This novel family of proteins was dubbed DDB1–CUL4A-associated 
WD40 domain proteins (DCAF proteins), and includes DDB2, a protein mutated in the cancer pre-
disposing syndrome xeroderma pigmentosum. However, given the connection to DNA repair a 
much broader role in cancer and in the sensitivity to DNA damaging treatments seems likely. 
Methods are continually being improved for the global identification of ubiquitinylation 
sites100, and to identify substrates in specific pathways101. In addition to MS approaches, protein 
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arrays are valuable tools for identifying substrates for PTMs. As these assays are done in vitro 
versatile manipulations and comparisons are possible.  Protein microarrays displaying >8,000 
human proteins were exposed to cell extracts that replicate the mitosis checkpoint and anaphase 
release in order to identify targets of the anaphase-promoting complex  (APC)102. APC is a 
multiprotein complex with E3 ubiquitin ligase activity that promotes cell cycle progression during 
mitosis.  Its substrates include mitotic cyclins, but also many other proteins that orchestrate this cell 
cycle transition. The array based ubiquitinylation assay compared extracts containing inhibited and 
activated APC, detecting most of the known substrates, and seven potential new substrates.  A 
similar experiment was used to identify and compare substrates for NEDD4 and NEDD4L103. In 
addition to shared substrates, NEDD4 showed a preference for tyrosine kinases, and NEDD4 
knockdown sustained tyrosine kinase signalling. NEDD4 family members regulate a variety of 
pathways and cellular functions that are implicated in cancer, such as many RTK pathways and 
transcription factors, and are found overexpressed in breast, prostate and pancreatic cancers104.  
This brief description of PTM aberrations in cancer is far from complete, and there are 
many other PTMs that are altered in cancer (Box 3). However, PTMs are emerging as important 
drug targets. The high hopes and resources invested in kinase inhibitor drugs are inextricably linked 
to their ability to prevent regulatory phosphorylations of critical substrates. We soon may witness 
similar prolific efforts to target other PTMs for cancer therapy, such as ubiquitinylation92. Notably, 
the validation of PTM targets is critically enabled by proteomics. PTMs are largely invisible in 
genomic studies and in order to fully exploit their therapeutic potential it will be necessary to 
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understand the dynamics of PTM turnover. It is tempting to speculate that PTM dynamics also 
contribute to the well known heterogeneity in cancer. Dynamic changes in protein expression and 
localisation can determine the drug sensitivity of cancer cells105 and dynamic changes in PTMs 
could vastly expand the window of opportunities of cancer cells to escape adverse conditions and 
therapy.   
 
Towards single cell proteomics 
New techniques enabling the functional analysis of individual cells are increasingly being used to 
address the heterogeneity of cancer cells, especially in terms of drug resistance. One of the first 
methods was Phospho-flow, invented by the Nolan group98.  This technique uses phospho-specific 
antibodies to label antigens in fixed cells. Subsequent analysis by flow-cytometry gives data on the 
single cell and population level that allow the investigation of heterogeneity and are applicable for 
the modelling of cancer signalling pathways 106.  More recently, Cohen et al. tagged ~1000 individual 
endogenous proteins in lung cancer cells with a fluorophore and monitored their expression and 
subcellular location by automated time lapse imaging105. Treatment with the topoisomerase 1 
inhibitor camptothecin caused the rapid relocation of proteins associated with the mechanism of 
drug action and slower changes in protein abundance. Interestingly, while most drug induced 
responses were similar in individual cells across the population, a subset of 24 proteins showed high 
cell to cell variability a day after drug exposure.  The upregulation of two of these proteins, the RNA 
helicase DEAD box polypeptide 5 (DDX5) and replication factor C1 (RFC1), correlated with drug 
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resistance and cell survival, showing that escape mechanisms can result from changes in protein 
dynamics that are unique to a subset of a cell population. This is an intriguing proposition for the 
development of drug resistance that warrants further investigation in preclinical cancer models. 
A different approach used a microfluidic platform that traps ~1000 individual cells and 
analyses their behaviour using imaging, optical indicator dyes and fluorescent antibodies4. This 
platform was used to assess the signalling dynamics of normal human haematopoietic stem cells 
(HSCs) and CML stem cells (CML-SCs) in response to the second generation BCR-ABL1 inhibitor 
dasatinib. While significant differences in the responses of individual cells were observed, on the 
population level dasatinib was more cytotoxic to HSCs than CML-SCs, but strongly and selectively 
inhibited migration of CML-SCs. Thus, single cell analysis can reveal important information on 
divergent and synchronised behaviour within cell populations, especially in regard to drug action. It 
would be fascinating to combine these approaches in order to collect deeper information on cancer 
cell heterogeneity. 
 
Perspective 
Although the work discussed in this Review represents only a small fraction of studies, it illustrates 
the power of functional proteomics in mapping cancer signalling pathways. The biggest challenge is 
to bring the proteomics technologies to clinical applications. Despite impressive progress especially 
in biomarker discovery [Au; unfortunately the article that discusses this will not be included in the 
focus issue.], substantial hurdles remain. Most current proteomics technologies are too slow, too 
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complex and too expensive to be used in the clinical laboratory, and the existence of many different 
experimental approaches leaves a deficit in standardisation. However, further innovations that may 
overcome these barriers are on the horizon. While MS is dominating the field, alternative 
technologies are appearing. Great progress is to be expected from array-based methods, optical 
methods and micro-engineering approaches. Although these methods cannot identify proteins de 
novo, their attractiveness lies in their multiplexing capabilities, throughput and prospect of reducing 
the costs of analysis. In particular, methods based on flow-cytometry, protein and tissue 
microarrays and micro-engineered devices are amenable to adaptation to the clinical laboratory. 
Our capability to routinely identify or test thousands of proteins per analysis has shifted the 
bottleneck towards data analysis and interpretation. The increasing use of advanced bioinformatics 
and systems biology tools is beginning to unlock network properties107. Recent examples are the 
development of a predictor for breast cancer prognosis based on the modularity of protein 
interaction networks108, and the identification of cancer-associated phosphorylation networks 
through the combined alignment of conserved phosphorylation sites and kinase-substrate 
networks109. This work also showed that we still miss large parts of phosphorylation networks.  
As we only begin to apply proteomics to unravel the role of other PTMs, such as 
ubiquitinylation, sumoylation and glycosylation, in signalling we can expect a further stream of 
data. It will be a challenging but informative task to understand the regulatory interplay between the 
different PTMs both on the level of individual proteins and on networks. In addition, these 
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investigations may provide molecular functions that can serve as biomarkers for cancer and thereby 
bridge the current gap between mechanistic understanding and mainly phenomenological markers.  
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Box 1. Quantitative proteomics. 
Mass spectrometry (MS) is not an a priori quantitative method, but several approaches have been 
developed to circumvent this problem. Most modern MS approaches are (semi)quantitative, and 
this has proven key to the success of proteomics to unravel signalling networks. The most used 
methods comprise110: 
2D-polyacrylamide gel electrophoresis (PAGE): The sensitivity, linear dynamic range and 
robustness of this method has been greatly improved by the use of fluorescent stains and tags111, and 
the analysis significantly simplified by a number of automated software packages. Proteins are 
identified by MS. 
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Isotopic labelling: The ability of MS to resolve heavy and light isotopically labelled molecules has 
been extensively used to design approaches for quantitation112-115. The common labelling methods 
are: metabolic, typified by stable isotope labelling with amino acids in culture (SILAC)116-118. Samples 
are grown on media containing either a normal or isotopically labelled form of an amino acid or 
food source119.  Comparison of protein abundance uses the light and heavy peaks observed in the 
mass spectrum. SILAC is best suited for cultured cells, but has also been used to label whole 
animals120 . Chemically reactive, isotopically labelled reagents are used to tag the protein or peptides 
(such as isotope-coded affinity tag, ICAT121, isobaric tag for relative and absolute quantitation, 
iTRAQ122). For absolute quantification (AQUA, isotopically labelled peptides are added to the 
sample as an internal standard for quantification123.   
Label-free: improvements in the robustness and reproducibility of both MS and chromatography 
paved the way for direct comparisons between MS data sets using retention time, mass and ion 
intensity124, 125.  As it is uncomplicated and reasonably reliable, it may become the method of choice 
for proteomics experiments. 
Antibody arrays. the repertoire of antibodies with highly selective binding to native or post-
translationally modified protein epitopes has expanded rapidly, and the arrays based on these have 
been used extensively to quantify the antigen126, 127.  This has now developed into a thriving business, 
with many companies offering commercial and bespoke custom arrays.  
In situ fluorescence: the use of a fusion protein approach, where the protein of interest is genetically 
fused to green fluorescent protein (GFP) or the range of analogues that have now been developed, 
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can determine the cellular localization and abundance of the protein using fluorescence 
microscopy128.  Automated methods for tracking cells and determining abundance and localization 
are only just becoming available. 
 
Box 2. Kinase profiling and kinomics 
Kinase profiling refers to the process of screening kinase inhibitors for activity and selectivity129.  
Given the role that aberrant kinase activity plays in cancer, and the huge efforts in the study of 
kinases and their substrates and inhibitors, the increase in the number of kinase inhibitors being 
translated into anti-cancer drugs in recent years is not surprising (it is estimated around a third of 
all major clinical trials currently involve kinase inhibitors).  However, it was only in 2001 when the 
first kinase inhibitor (imatinib) received clinical approval. 518 kinases were initially predicted from 
analysis of the human genome130, of which the vast majority have now been validated, and >400 of 
these are currently available in various screens. However, this is unlikely to be the full story, as new 
kinases are being identified and tissue specific roles are being elucidated131.   
Methods to identify kinases generally rely on the use of peptide substrates, either in 
microtitre plate, bead or array format, that can be used to measure the activity of a set of purified 
kinases, although with recent improvements132-135, methods are getting closer to the native in vivo 
conditions.  Miniaturization through microfluidics and new detection methods are greatly 
improving sensitivity and reducing costs.  The benefits are obvious:  it is highly parallelised, so 
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many compounds and kinases can be tested, and the quantitative analysis allows the critical 
question of off-target activity to be addressed.  
Kinomics,130 is formally the identification of kinases at the genetic, or preferably proteomic, 
level.  However, this should be expanded to include the challenging task of identifying kinase targets 
and elucidating the cellular pathways and networks in which they are involved and the complex 
regulation of these. Proteomics approaches coupled to modelling through systems biology methods 
are in the vanguard of the techniques being applied.  A grand challenge remaining is the 
identification of the actual downstream effector kinases that are the best drug targets. Furthermore, 
chemical proteomics is a valuable tool to identify on- and off-target interactions of individual kinase 
inhibitors136. 
 
Box 3. Other post-translational modifications (PTMs) 
Protein function is critically regulated by PTMs, and the role of PTM aberrations in the faulty 
regulation of cancer signalling networks is increasingly appreciated. Proteomics is currently 
expanding its scope beyond phosphorylation, delivering exciting results on other PTMs such as: 
Acetylation and methylation: The regulation of gene expression exerted by the acetylation and 
methylation of lysines and arginines in histones is well established, and the nickname “histone 
code” highlights the importance of this epigenetic control137. Silencing of tumour suppressor gene 
expression due to subversion of the histone code is well known137. However, proteomics has enabled 
a systematic study of these histone modifications138. Importantly, proteomics identified many other 
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chromatin-independent targets.  For instance, stable isotope labelling with amino acids in culture 
(SILAC) analysis of breast cancer cells treated with vorinostat, a histone deacetylase (HDAC) 
inhibitor, revealed changes in the expression of transcription factors, metabolic, structural, 
chaperone and cell cycle proteins139.  HDAC6 was identified to inhibit EGFR endocytosis by 
deacetylating microtubules140.  
Acylation: A well characterised cancer relevant example is the modification of Ras proteins by 
farnesylation, geranylation and palmitoylation, which localises Ras proteins to distinct membrane 
compartments141. As Ras mutations are frequent in human cancers, the Ras modifying acylases 
became major drug targets, unfortunately with disappointing clinical results142. Much effort was 
invested to understand the opportunities and failures, but quantitative proteomic techniques were 
only recently developed to identify palmitoylated proteins143,  
Oxidative modifications and cysteine nitrosylation: have also been shown to play an important role 
in signalling144. A role in cancer is highly likely due to the hypoxic and inflammatory environment, 
but systematic proteomics studies are lagging behind. 
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Figure Legends 
Fig. 1. The EGFR signalling network.  Upon activation (by ligand binding), the epidermal growth 
factor receptor (EGFR, also known as ERBB1) autophosphorylates tyrosine residues in its 
cytoplasmic domain, which serve as docking sites for the assembly of protein complexes that 
transduce EGF signals to generate specific biological responses. It is unlikely that the full 
complement of binding partners is recruited to each receptor, and rather more plausible that 
individual EGFRs form complexes with different compositions. In addition, all four members of the 
ErbB family (EGFR, ERBB2 (also known as HER2), ERBB3 and ERBB4) can form heterodimers (not 
shown), which share common binders but due to the different representation of docking sites 
assemble receptor complexes with different signalling properties27.  The EGFR network has been 
reviewed in detail elsewhere145, 146, and only the better characterised downstream pathways are 
shown here. Kinases are light blue; scaffolds are dark blue; adaptor proteins are yellow; G-proteins 
are green; transcription factors are orange; phospholipase C (PLC is a phospholipase; CBL is a 
ubiquitin ligase; son of sevenless homologue (SOS) is a guanine nucleotide exchange factor. Small 
molecule second messengers are in red: phosphatidylinositol 4,5-bisphosphate (PIP2),; 
diacylglycerol (DAG), inositol 1,4,5-triphosphate (IP3), and Ca2+.  The pathway discussed in this 
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review is the ERK pathway, which is initiated through the recruitment of a protein complex 
containing the Src homology 2 domain containing (SHC) and growth factor receptor-bound 
protein 2 (GRB2) adaptor proteins and the exchange factor SOS to the activated EGFR. SOS 
exchanges GDP for GTP on Ras, which induces a conformational change that enables Ras to bind 
Raf kinases with high affinity. Raf activation is a complex process involving dephosphorylation, 
phosphorylation, homo- and hetero-dimerisation and binding to the kinase suppressor of ras 1 
(KSR1) scaffold147-149. Activated Raf phosphorylates and activates MEK, which in turn 
phosphorylates and activates ERK. ERK exerts its different biological effects through a large number 
of substrates32 including transcription factors.  AP1, activator protein 1; CAMK, 
calcium/calmodulin-dependent protein kinase; CREB, cAMP responsive element binding protein; 
EGR1, early growth response 1; FAK, focal adhesion kinase; MEF2, myocyte enhancer factor 2; 
PKC, protein kinase C; STAT, signal transducer and activator of transcription. Please check 
definitions carefully.] 
 
Fig. 2. The BCR-ABL1 signalling network. Breakpoint cluster region (BCR)-ABL1 activates 
downstream signalling pathways through a core network of 7  closely associated proteins36. They 
comprise adaptor proteins (blue), phosphatases (orange), and the regulatory p85 subunit of PI3K 
(green) [Au; please note that this was changed according to the redrawn figures, which I will send to 
you soon.]. Selected downstream signalling pathways  are depicted in light green and biological 
outcomes in yellow. Most biological effects are regulated through multiple pathways, for example 
 52
actin polymerisation is regulated through the GRB2-related adapter protein 2 (GRAP2, also known 
as GADS)- lymphocyte cytosolic protein 2 (LCP2, also known as SLP76)-Nck adaptor pathway150, or 
SHIP2 regulation of phosphatidylinositol-3,4,5-trisphosphate levels151. The scheme is highly 
simplified for clarity. Arrows do not imply direct connections and may summarize several steps. 
Based on data from Brehme et al.36  AP2, adaptor protein complex 2; CSK, c-src tyrosine kinase; 
GRB2, growth factor receptor-bound protein 2; SHC1, Src homology 2 domain containing 1; STS1, 
suppressor of T-cell receptor signaling 1.  
Fig. 3. The ubiquitin system. Ubiquitin (Ub) is a small protein that is transferred as a versatile 
regulatory post-translational modification (PTM) to target proteins in a three step process152. In the 
first step an E1 ubiquitin-activating enzyme uses ATP to form a covalent thioester with ubiquitin. 
E1 then transfers the ubiquitin moiety onto an ubiquitin-conjugating enzyme E2. E2 associates with 
one of several hundred E3 ubiquitin ligases which provide specificity by also binding the target 
protein. The E2 binding and target recognition domains can reside in one protein (as shown) or in 
different proteins that a part of a ligase complex. Finally, the ubiquitin moiety is transferred to a 
lysine residue in the target protein directly or through an E3-ubiquitin ligase. Further ubiquitins can 
be added to lysines in ubiquitin itself. Dependent on the number of ubiquitin moieties transferred 
and the linkage type ubiquitinylation can have different functions that are often derailed in cancer83 
and many other diseases153. 
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At-a-glance summary 
• Signalling pathways are commonly deranged in cancer and quantitative proteomics offers powerful 
approaches to map these pathways and their aberrations in cancer. 
• Hubs in signalling pathways feature multiple protein interactions, which are involved in information 
processing and specification of the biological responses. These networks can be mapped by interaction 
proteomics to reveal molecular mechanisms of transformation as well as potential targets for therapeutic 
interventions. 
• The oncogenic actions of the epidermal growth factor receptor (EGFR) network and the breakpoint cluster 
region (BCR)-ABL1 oncogene rely on the dynamic assembly of multiprotein complexes, which activate 
multiple downstream pathways that cooperate in transformation. In EGFR networks the oncogenic potential 
increases with the number of downstream pathways being activated. 
• The dynamic assembly of protein complexes is regulated by post-translational modifications (PTMs), such 
as  phosphorylation. Advances in phosphoproteomics allow both the targeted and global mapping of 
phosphorylation networks confirming that kinase networks play major roles in cancer and offer numerous 
new targets for therapeutic intervention. 
• In addition to phosphorylation, a role for PTMs in the regulation of cancer cell biology is becoming 
increasingly recognised. For instance, proteomic studies of ubiquitination are beginning to unravel extensive 
alterations that contribute to key alterations of cancer, such as growth factor receptor activation, 
transcription factor function, protein localisation and degradation.  
 54
• Dynamic changes in protein abundance and PTMs may also contribute to cancer cell heterogeneity, and 
new proteomics technologies based on optical, spectroscopic and microarray methods are being developed to 
analyse individual cells. 
 
Glossary 
Chemical biology. Using chemicals, usually drugs or drug-like compounds, to probe biological systems to 
measure the response of biological systems to perturbations, but in proteomics it also increasingly refers to 
the use of affinity reagents to enrich classes of proteins for further analysis. 
Chemical genetics. A part of chemical biology that focuses on the use of chemicals to explore genetic 
systems as well as genetic factors that determine drug sensitivity. 
Matrix management. A flexible management approach that assigns people with the required skill sets to 
projects, typically drawing expertise from different departments. This comparison is used to illustrate that a 
protein with a defined molecular function, such as a kinase, can be employed by several different pathways. 
Modularization. The grouping of different functions into a single unit (module) so that the output of the 
module can be treated as a single functional entity, such as the ability of different combinations of 
components of protein complexes to achieve the same output. 
SH2 domain. Src homology 2 domains were first discovered as conserved domain in the Src kinase family. 
SH2 domains recognize short peptide motifs containing a phosphorylated tyrosine residue., and thus 
function as phosphotyrosine dependent protein interaction sites.   
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Non-oncogene addiction. This occurs when the action of oncogenes needs to be supported by apparently 
normally functioning signalling pathways that allow the mutated oncogene to develop its transforming 
activity. 
Stable isotope labeling with amino acids in cell culture (SILAC). This method involves the in vivo 
metabolic labelling of samples with amino acids that carry stable (nonradioactive) heavy isotope 
substitutions of atoms which when analyzed by MS produces so-called ‘conjugated’ peptide peaks, which 
originate from the same protein but show a characteristic mass shift corresponding to the mass difference 
between the light and heavy label; the relative intensity of conjugated peak pairs provides the relative 
abundance in the two samples.  
Nodes. Describes objects in graph, while the connections between objects are termed edges, and in signalling 
networks nodes represent proteins (or genes, if they are based on genetic information), and edges represent 
the relationship between the nodes, such as binding, regulation or modification. 
Scaffold proteins. Proteins that are able to simultaneously bind two or more other proteins, and thereby 
facilitate physical and functional interactions between their client proteins.  
The Warburg effect. Named after a discovery made by the German biochemist Otto Warburg in the 1920’s 
that cancer cells predominantly use anaerobic glycolysis rather than oxidative phosphorylation even when 
oxygen is abundant, and as a result pyruvate is converted to lactate instead of being oxidised by the 
mitochondria. 
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O-linked N-acetylglucosamine acylation. (O-GlcNAcylation) A form of glycosylation found in nuclear and 
cytosolic proteins where O-GlcNAc is added to the hydroxyl groups of serine and threonine residues that can 
also serve as phosphorylation sites. 
iTRAQ (isobaric tag for relative and absolute quantitation). A stable isotope labelling method for the 
quantitation of peptides by MS, where a molecule containing either normal or heavy isotopes is used to 
chemically modify the proteins or peptides from each individual sample, and the fragmentation of the 
labelled molecules gives rise to specific reporter ions that can be used to measure the relative amounts 
present in each sample. 
IMAC (immobilized metal ion affinity chromatography).A method for the enrichment of phosphopeptides 
exploiting the propensity of metal ions like iron or gallium to bind phosphate groups. 
Electron transfer dissociation (ETD).A recently introduced MS method for the fragmentation of molecules 
by transferring electrons from anion radicals to the positively charged ions; it is a non-ergodic process (rapid, 
kinetically controlled) so energy is not redistributed and many bonds are broken in the molecule, not just the 
weakest ones as seen in collision-induced dissociation.  
Collision-induced dissociation (CID).A common MS fragmentation method where energy is transferred to 
ions thermally through collisions with an inert gas, giving a vibrational activation fragmentation process that 
is thermodynamic (the energy has time to redistribute through the molecule) and tends to break mainly the 
weakest bonds in the structure. 
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Cyclins. Regulatory subunits that are essential for the activity of cell cycle dependent kinases (CDKs). Their 
name derives from their periodic expression during the cell cycle, which is due to the regulated degradation 
by the ubiquitin-proteasome system that is thought to drive the cell cycle.  
WD40 domains. Protein domain consisting of 4-16 repeats of an approximately 40 amino acid long motif 
ending with a W-D (tryptophan-aspartic acid) di-peptide. The WD40 domains form a circular β-sheet 
propeller structure that serves as a structural platform for protein interactions, while the specificity of the 
interactions is determined by sequences outside of the WD repeats. 
Micro-engineering. The use of micro-fabricated devices with small (micron) scale features (channels, wells, 
vessels, etc) to allow the processing of small volumes of fluid. 
Micro-Western Arrays.A miniaturized version of the traditional Western blotting procedure, where robotics 
are used to mutiplex the running and blotting of miniaturized gels. 
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